Overview

Amifostine in Treating Patients With Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2001-02-12
Target enrollment:
Participant gender:
Summary
RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Amifostine